source
- Eli Lilly lifts guidance by $10 billion as GLP‑1 sales outpace expectationsEli Lilly said its latest financial guidance is $10 billion higher than previously forecast, driven by strong sales of its GLP‑1 medicines. The company’s commercial performance has repeatedly excee…
- Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellersEli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.